Germany breast cancer therapeutics market is estimated to grow significantly at a CAGR of around 8.9% during the forecast period. Increasing the incidence of breast cancer coupled with a growing awareness program towrds breast cancer diagnosis and treatment are the major factors that contributing to the growth of the market. According to the WHO, in 2018 there were 71,888 new cases of breast cancer in Germany. The growing cases of breast cancer in the country further propels thed demand for diagnostics and further treatment facilities for breast cancer thus contributing to the market growth. The statutory early detection program offers women above 30 years of age an annual palpation examination by a physician. According to the quality assured Mammography Screening Program in Germany, and women between 50 and 69 years of age are invited to an X-ray examination of the breasts every two years.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/germany-breast-cancer-therapeutics-market
Germany breast cancer therapeutics market is segmented on the basis of therapy. The therapy segment is further classified into chemotherapy, hormone therapy, targeted therapy, radiation therapy and others (surgery). Among all therapies, the chemotherapy market held the largest market share in the Germany breast cancer therapeutics market. Chemotherapy is most used when cancer in the lymph nodes and irrespective of tumor size or menopausal status. Along with that it is used for the treatment of breast cancer in premenopausal women and referred for those women who diagnosed with early stage breast cancer for hormone receptor negative and HER2 positive cancer. The types of chemotherapy include adjuvant chemotherapy and neoadjuvant chemotherapy. The adjuvant chemotherapy is used to destroy cancer cells that have been spread and not seen by the imaging tests. This method helps in reducing the cancer cells that form a new tumor in the other place of the body. Adjuvant chemotherapy reduces the risk of breast cancer coming back. Neoadjuvant chemotherapy can be used to reduce the size of the tumor, so it can be removed with less widespread surgery.
The companies which are contributing to the growth of the Germany breast cancer therapeutics market include AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Mylan NV, Novartis International AG, F. Hoffmann-La Roche AG, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
A full report of Germany Breast Cancer Therapeutics Market available @ https://www.omrglobal.com/industry-reports/germany-breast-cancer-therapeutics-market
Germany Breast Cancer Therapeutics Market Segmentation
By Therapy
- Chemotherapy
- Hormone Therapy
- Targeted Therapy
- Radiation Therapy
- Others (Surgery)
